Brief: Alligator Bioscience To Initiate Phase 3 For Mitazalimab in 2025

Alligator Bioscience AB

06/02/2025 07:46

Feb 6 (Reuters) - Alligator Bioscience AB  ATORX.ST :
    * PHASE 3 INITIATION IN 2025 FOR MITAZALIMAB IN PANCREATIC
CANCER
    * FDA: FEEDBACK VALIDATES CLINICAL DEVELOPMENT STRATEGY AND
PHASE
3 DESIGN
    * FDA: FEEDBACK CONFIRMS TOXICOLOGY PACKAGE SUFFICIENT FOR
BLA
SUBMISSION
    * COMPLETES END OF PHASE 2 MEETING WITH FDA
    * FDA AGREES ON DATA PACKAGES SUPPORTING BLA AND PHASE 3
DESIGN

Source text:  ID:nMFN4c0XyR 
Further company coverage:  ATORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))